Highly concentrated solutions are disclosed along with methods of inhibiting and/or ameliorating functional neurological disorders of the brain. The method may include administering directly to a brain of a subject a medicament multiple times over a time period of at least two days. The medicament may include a half-life of less than 2 hour in the cerebrospinal fluid. The method may include inhibiting and/or ameliorating a functional neurological disorder of the brain using the medicant.

An object of the present invention is to provide a novel composition which suppresses or improves depression. The present invention provides a composition for use in suppressing or improving depression, comprising Lactobacillus paracasei as an active ingredient. In the present invention, the depression can be a condition which occurs in daily life. The composition of the present invention can be provided as a food composition and a supplement, and can be provided to a human so that Lactobacillus paracasei is ingested in a daily amount of 1 mg or more in terms of dry cell mass or 10 to 10.sup.11 cells.

An object of the present invention is to provide a novel composition which suppresses or improves depression. The present invention provides a composition for use in suppressing or improving depression, comprising Lactobacillus paracasei as an active ingredient. In the present invention, the depression can be a condition which occurs in daily life. The composition of the present invention can be provided as a food composition and a supplement, and can be provided to a human so that Lactobacillus paracasei is ingested in a daily amount of 1 mg or more in terms of dry cell mass or 10 to 10.sup.11 cells.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

Provided is a biomarker for bipolar disorder, comprising Syt7 gene and/or an expression product thereof. Also provided is use of the Syt7 gene and/or the expression product thereof in the preparing a medicament for treating bipolar disorder. By monitoring the Syt7 gene and/or the expression product thereof, medicaments for treating bipolar disorder can be screened, thus providing support for diagnosis and treatment targeting Syt7 molecules.

Provided is a biomarker for bipolar disorder, comprising Syt7 gene and/or an expression product thereof. Also provided is use of the Syt7 gene and/or the expression product thereof in the preparing a medicament for treating bipolar disorder. By monitoring the Syt7 gene and/or the expression product thereof, medicaments for treating bipolar disorder can be screened, thus providing support for diagnosis and treatment targeting Syt7 molecules.

Disclosed herein are compositions and methods of treating neuropsychiatric and cognitive conditions with single, repeat and/or extended release 5-HT receptor agonist dosage forms.

Disclosed herein are compositions and methods of treating neuropsychiatric and cognitive conditions with single, repeat and/or extended release 5-HT receptor agonist dosage forms.

Provided herein are methods for preventing or treating a psychological disorder. A serotonin agonist or an agonist of serotonin receptors is administered separately, sequentially or simultaneously in combination with a serotonin receptor 2A antagonist.

A nitrogen-containing ring derivative regulator, a preparation method therefor and use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof as a G protein-coupled receptor regulator in the treatment or prevention of central nervous system diseases and/or mental diseases.

##STR00001##